ARCHIVES

Cyramza-Docetaxel Combination Extends OS In Second-Line NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

Is a New Cancer Center Always a Good Thing? UCSD To Buy Las Vegas Center at Bankruptcy Sale

January 20, 2012

NCI Role, Issues In Education Considered By DRCCA Board

August 21, 1981

FDA News: FDA Approves Reagent System for Graft-Versus-Host Disease

January 24, 2014

UPCI To Lead Clinical Trials Of Eli Lilly’s Oncology Agents.

July 6, 2001

Obesity, Faster Weight Gain, Linked To Poor Prognosis

October 28, 2005

Data Presented At Scientific Meetings Can Have Impact On Patient Treatment

March 31, 2006